Equities
There are no signs of broader financial stress in the Chinese corporate sector. The most recent financial market turmoil has had no systemic damage to corporate sector balance sheets. We are leaning against being overly bearish. Current valuation readings, particularly for Chinese H shares and Hong Kong stocks, on a historical basis have never been sustainable.
Yesterday's Weekly Report showed a table of sector operating margins relative to their long-term average, as well as price/sales ratios. Expensive sectors with above average margins appear particularly vulnerable in an environment where overall margins are being squeezed and economic risks are mounting. The consumer discretionary sector stands out as having significant profit margin and valuation downside. The policy backdrop is also turning more hostile. History shows that this sector outperforms when interest rates are falling and/or low, and underperforms when they climb and credit becomes more restrictive. This correlation is evident in the correlation between relative performance and money supply. When the cost of credit is low and liquidity is plentiful, investors discount increased discretionary consumer spending, particularly on durables, and bid stocks up accordingly. The opposite is also true. Currently, money growth is plunging, although remains in positive territory for the time being, suggesting that credit creation is slowing. Importantly, the longer that financial markets stay turbulent, the greater the upward pressure on the personal savings rate and likelihood that discretionary spending is reined in. Even then, a consumption contraction is not a prerequisite for consumer discretionary underperformance. With the Fed determined to keep pushing up interest rates, the macro backdrop is bearish for discretionary stocks.
Growth stocks have trounced value indexes over the last few years. The bulk of our style Indicators signal that macro conditions are still tilted in favor of growth. As a reminder, growth indexes almost always move to a premium when economic growth declines, as is currently the case. Nonetheless, we are losing conviction in the ability of growth stocks to sustainably outperform from current levels, despite our downbeat view of global economic growth prospects. Comparing the genetic makeup of the growth and value benchmarks with our current sector positioning suggests extrapolating recent gains is becoming higher risk. Growth indexes have nearly quadruple the tech exposure of value indexes, at the 32% vs. 8%. Consumer discretionary, another underweight, represents 18% of growth indexes vs. 7% of value indexes. That is a 35% weighting difference from two sectors. Meanwhile, the defensive telecom services and utilities sectors are 10% of value exposure, but only 3% of growth benchmarks. Importantly, growth stocks have a checkered past once equity bear markets and/or recessions set in. Since 1960, value has outperformed in 80% of bear markets. Value has also outperformed in 5 out of the 8 recessions since that time. While neither recession nor bear market is guaranteed at the moment, both are becoming higher probabilities. Adding it all up, we are moving to neutral in our growth vs. value bias after a 10% gain. Please see yesterday's Weekly Report for more details.
Equity selloff alone will not catch the Fed's eye unless there is an outright crash.
An oversold bounce may be getting underway, but without a policy assist, it would be a rally to sell. Go to neutral in the growth vs. value trade and beware sub-surface weakness in the consumer discretionary sector.
The previous Insight showed that S&P pharmaceutical index outperformance is well supported by both endogenous and exogenous forces. The same is not true for the riskier biotech space. As discussed in previous research, biotech stocks have exhibited all of the characteristics of a mania. Now the forces that propelled the group higher are working in reverse. Speculation is rapidly being reined in, warning that the flows into biotech stocks are drying up. Margin debt has crested, reinforcing that the high-octane fuel to support momentum stocks is starting to evaporate. Biotech IPOs are going from feast to famine: if share prices continue to fall, expected returns will follow suit, warning against expecting further capital inflows. Consequently, we expect biotech stocks to remain on the mania track, which has not entered the bubble-bursting phase (top panel).
Pharmaceutical stocks have broken from their correlation with biotech stocks, and we expected this divergence to be sustained. Pharmaceutical profits remain one of the few bright spots within the corporate sector. Drug demand continues to boom, as measured by consumer spending data. Inventories have moved higher at both the wholesale and manufacturing level, but this appears to reflect demand-driven stocking of product, given ongoing strong pricing power gains. In a deflationary world, the ability to significantly lift selling prices warrants a premium valuation. Yet the S&P pharmaceuticals index still trades at a large discount to its historic average relative valuation. If domestic economic disappointment mounts, as we expect, it will provide another catalyst for a relative performance re-rating. Stay overweight the S&P pharmaceuticals index. Importantly, it will be important to differentiate pharma from biotech, please see the next Insight.
Taiwan's opposition Democratic Progressive Party is poised to win the presidency and possibly the legislature in elections January 16. The result will be icier cross-strait relations in the coming years that will add a geopolitical headwind to Taiwanese assets, even as it struggles to cope with a low-growth world. Taiwan still has advantages over other emerging markets, but its outlook is darkening.
